FDA clears JenaValve Trilogy for severe aortic regurgitation

JenaValve said the FDA has granted premarket approval for its Trilogy Transcatheter Heart Valve System for patients with symptomatic, severe aortic regurgitation who are at high or greater risk for surgical aortic valve replacement, making it the first FDA-approved transcatheter device in the U.S. for this indication. The approval is based on data from the ALIGN-AR program, which evaluated the Trilogy system in high-risk patients with native aortic regurgitation, a population that has had limited catheter-based treatment options because most transcatheter valves were designed for calcified aortic stenosis, not regurgitant valves. (jenavalve.com)

Why it matters: For veterinary professionals watching device regulation and translational cardiology, the approval is another sign of how regulators are opening narrower, high-need structural heart indications when sponsors can show strong procedural performance in hard-to-treat patients. ACC coverage of ALIGN-AR reported a device success rate of 96.4%, low residual regurgitation at 30 days, favorable ventricular remodeling measures, and low valve embolization rates, underscoring how device design tailored to valve anatomy can expand minimally invasive care where off-label approaches have been challenging. The broader FDA device picture is moving in parallel toward earlier, more targeted cardiovascular detection tools as well, including a separate 510(k) clearance for Anumana’s AI-enabled software that uses standard 12-lead ECGs to flag early pulmonary hypertension patterns and was developed on more than 250,000 Mayo Clinic patient records. (acc.org; PharmaShots)

What to watch: Next comes real-world adoption, center training, reimbursement and coverage decisions, and any FDA post-approval study requirements that shape how quickly Trilogy moves into routine structural heart practice. More broadly, recent cardiovascular device clearances also suggest regulators are increasingly comfortable with narrower tools that fit into existing workflows, such as ECG-based software that can integrate with EHR and ECG management systems without moving patient data outside the health system. (jenavalve.com; PharmaShots)